Myomo Makes NYSE American Section 610(b) Public Announcement


Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 12, 2019 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2018 included in the 10-K contained an audit opinion from its independent registered public accounting firm, which included a going concern emphasis of matter paragraph.

This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires separate public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Companys consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2018.

About Myomo Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patients own EMG signals through non-invasive sensors on the arm, can restore an individuals ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit

Forward Looking Statements This press release contains forward-looking statements regarding the Companys future business expectations, including the potential benefits of Myomos products for their users, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

  • our sales and commercialization efforts;
  • our ability to achieve reimbursement from third-party payers for our products;
  • our dependence upon external sources for the financing of our operations;
  • our ability to effectively execute our business plan; and
  • our expectations as to our clinical research program and clinical results.

More information about these and other factors that potentially could affect our financial results is included in Myomos filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Companys annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

For Myomo:
[email protected]


Vivian Cervantes
PCG Advisory
[email protected]


Matter Communications
Sarah Karr
[email protected]